NEW YORK, Oct. 28, 2018 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court and further details about the cases can be found at the links provided. There is no cost or obligation to you.
Tribune Media Company (: TRCO)
Class Period: November 29, 2017 - July 16, 2018
Lead Plaintiff Deadline: November 13, 2018
Join the action: https://www.zlk.com/pslra-1/tribune-media-company-loss-form?wire=3
The lawsuit alleges: Tribune Media Company made materially false and/or misleading statements throughout the class period and/or failed to disclose that: (1) Sinclair Broadcasting Group, Inc., which had agreed to merge with Tribune, was refusing to divest itself of television stations in certain markets necessary in order to secure regulatory approval; and (2) Sinclair was taking the position that it was not legally or contractually obligated to complete the identified divestitures to ensure regulatory approval.
To learn more about the Tribune Media Company class action contact [email protected].
Cocrystal Pharma, Inc. (NASDAQCM: COCP)
Class Period: September 23, 2013 - September 7, 2018
Lead Plaintiff Deadline: November 19, 2018
Join the action: https://www.zlk.com/pslra-1/cocrystal-pharma-inc-loss-form?wire=3
The lawsuit alleges: Cocrystal Pharma, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) defendants were engaged in a pump-and-dump scheme to artificially inflate Cocrystal’s stock price; (2) this illicit scheme would result in governmental scrutiny, including from the SEC; (3) defendants failed to abide by SEC disclosure regulations; and (4) as a result, defendants’ statements about Cocrystal’s business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
To learn more about the Cocrystal Pharma, Inc. class action contact [email protected].
AbbVie Inc. (: ABBV)
Class Period: October 25, 2013 - September 18, 2018
Lead Plaintiff Deadline: November 20, 2018
Join the action: https://www.zlk.com/pslra-1/abbvie-inc-loss-form?wire=3
The lawsuit alleges that, during the class period, AbbVie Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) AbbVie’s strategy to increase the sales growth of its blockbuster drug, HUMIRA, relied in part upon illegal kickbacks and unlawful sales and marketing tactics; (2) such practices would foreseeably lead to heightened scrutiny by State governments and agencies; and (3) as a result, Defendants’ public statements were materially false and misleading at all relevant times.
To learn more about the AbbVie Inc. class action contact [email protected].
You have until the lead plaintiff deadlines to request the court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
[email protected]
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com
